StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences r&D by cost type — Clinical studies and outside services / other costs ($M) ($M)

Form 10-Q / 10-K MD&A Research and Development Expenses

QuarterlyAnnual
Latest, Q2 2026
618
Period ended Jun 30, 2026
Change on a year earlier
-2.8%
636 in Q2 2025
History
25 quarters
Since Q1 2020
Sources
18
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedR&D by cost type — Clinical studies and outside services / other costs ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026618-2.8%Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗
Q1 2026Mar 31, 2026510-2.7%Form 10-Q (gild-20260331.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 2025673-2.0%Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗
Q3 2025Sep 30, 2025539-8.2%Form 10-Q (gild-20250930.htm, filed 2025-11-07) ↗
Q2 2025Jun 30, 2025636+22.3%Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗
Q1 2025Mar 31, 2025524-5.9%Form 10-Q (gild-20260331.htm, filed 2026-05-07) ↗
Q4 2024Dec 31, 2024687+17.4%Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗
Q3 2024Sep 30, 2024587-13.8%Form 10-Q (gild-20250930.htm, filed 2025-11-07) ↗
Q2 2024Jun 30, 2024520-16.0%Form 10-Q (gild-20250630.htm, filed 2025-08-07) ↗
Q1 2024Mar 31, 2024557-11.4%Form 10-Q (gild-20250331.htm, filed 2025-05-07) ↗
Q4 2023Dec 31, 2023585-21.1%Form 10-K (gild-20241231.htm, filed 2025-02-28) ↗
Q3 2023Sep 30, 2023681+47.7%Form 10-Q (gild-20240930.htm, filed 2024-11-12) ↗
Q2 2023Jun 30, 2023619+32.3%Form 10-Q (gild-20240630.htm, filed 2024-08-08) ↗
Q1 2023Mar 31, 2023629+26.8%Form 10-Q (gild-20240331.htm, filed 2024-05-08) ↗
Q4 2022Dec 31, 2022741–Form 10-K (gild-20231231.htm, filed 2024-02-23) ↗
Q3 2022Sep 30, 2022461-14.3%Form 10-Q (gild-20230930.htm, filed 2023-11-07) ↗

Cite this data

StockData. (2026). Gilead Sciences R&D by cost type — Clinical studies and outside services / other costs ($M) ($M), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rd_clinical_studies

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.